Table 2.
Cross-comparisons between individual tissues
| Gene | Tissue | Number of tissues | % (and number) of SD cross-comparison between: | ||
|---|---|---|---|---|---|
| Normal | Cancer | Individual normal tissues | Individual normal and cancer tissues | ||
| FLI1 | Breast | 6 | 10 | 33.3% (5/15) | 66.7% (40/60) |
| MMP9 | Breast | 6 | 12 | 6.7% (1/15) | 66.7% (48/72) |
| MMP2 | Breast | 4 | 6 | 50.0% (3/6) | 37.5% (9/24) |
|
| |||||
| AKT1 | Prostate | 4 | 6 | 16.7% (1/6) | 37.5% (9/24) |
| CSF1R | Prostate | 11 | 9 | 41.8% (23/55) | 38.4% (38/99) |
| ERBB2 | Prostate | 4 | 5 | 33.3% (2/6) | 35.0% (7/20) |
| FOSL2 | Prostate | 9 | 7 | 38.9% (14/36) | 47.6% (30/63) |
| HES5 | Prostate | 6 | 6 | 20.0% (3/15) | 27.8% (10/36) |
| HSP90AA1 | Prostate | 7 | 4 | 57.1% (12/21) | 46.4% (13/28) |
| MYC | Prostate | 6 | 5 | 6.7% (1/15) | 3.3% (1/30) |
| TGFB3 | Prostate | 6 | 4 | 33.3% (5/15) | 25.0% (6/24) |
SD, significantly different, based on a two-sample 1D KS test, P < 0.01.